Treating Schizophrenia by Correcting Abnormal Brain Development
The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease.
This study is funded by the National Institutes of Health.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
|Official Title:||Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex|
- Neurocognitive Functions [ Time Frame: 6 months ]
- Clinical symptoms [ Time Frame: 6 months ]
|Study Start Date:||November 2003|
|Estimated Study Completion Date:||July 2019|
|Estimated Primary Completion Date:||July 2018 (Final data collection date for primary outcome measure)|
Active Comparator: Antipsychotic plus study drug
Half of the subjects will receive the study medications in addition to their ongoing antipsychotic regimen.
Up to 36 mg daily
Placebo Comparator: Antipsychotics plus placebo
Half of the subjects will receive placebo in addition to their antipsychotic regimen.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00179465
|Contact: Noel Shaskan, B.A.||email@example.com|
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: T.-U. Wilson Woo, M.D., Ph.D. 617-855-2823 firstname.lastname@example.org|
|Principal Investigator: T.-U. Wilson Woo, M.D., Ph.D.|
|Principal Investigator:||T.-U. Wilson Woo, M.D., Ph.D.||Beth Israel Deaconess Medical Center, Harvard Medical School|